Lactococcus lactis C11JN Strain Produces Composite Antimicrobials

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Antibiotic resistance poses a significant challenge in treating bacterial infections, as bacteria develop resistance to current antibiotics, making it difficult to manage antibiotic-resistant infections effectively in humans and animals.

Innovation Solution

A novel Lactococcus lactis strain, Lactococcus lactis C11JN, is identified, which produces a range of bioactive compounds, including Nisin, Enterolysin, Subtilin, and Zoocin, with broad-spectrum antimicrobial activity against both gram-positive and gram-negative bacteria, providing a new treatment option that can be used alone or in combination with existing therapies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current antibiotics are used to treat bacterial infections, then treatment effectiveness is maintained against susceptible bacteria, but treatment fails against antibiotic-resistant bacteria

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidbroad-spectrum activity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the chemical structure and properties of antimicrobial agents by producing novel bioactive compounds (bacillaene, lacticin 3007, nisin Z, subtilin) with different mechanisms of action compared to conventional antibiotics, thereby overcoming resistance while maintaining effectiveness

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent combines multiple different bioactive compounds produced by Lactococcus lactis C11JN to create a composite antimicrobial preparation that targets bacteria through multiple mechanisms simultaneously, ensuring effectiveness against resistant strains

Inventive Principle:

Principle #40Composite materials

2Reliability

If new bioactive compounds are produced to overcome antibiotic resistance, then effectiveness against resistant bacteria is improved, but complexity of compound production increases

Engineering Contradiction:

Improveantimicrobial effectivenessVSAvoidproduction complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The Lactococcus lactis C11JN strain automatically produces multiple different bioactive compounds (bacillaene, lacticin 3007, nisin Z, subtilin) through its natural metabolic pathways when provided with appropriate nutrients, eliminating the need for complex external production systems

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

A single Lactococcus lactis C11JN strain serves multiple functions by simultaneously producing four different types of bioactive compounds with complementary antimicrobial mechanisms, simplifying the overall production system while maintaining broad effectiveness

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP3922309A1Novel lactococcus lactis strain for the production of bioactive compounds having antimicrobial effect

Publication Date: 2021.12.15 INNOVACIÓN & GESTÓN Y CONSERVACIÓN DE UNGULADOS SL (INGULADOS)

Figure 1

AI summary

Disclosed herein is a novel Lactococcus lactis strain, termed as C11JN and with deposit number DSM 33521 and antimicrobial compositions comprising said strain and/or bioactive compounds produced by said strain. This new strain and the bioactive compounds that it produces have shown to be useful to inhibit the growth of a wide-spectrum bacterial pathogens and, hence, to treat diseases produced by said bacterial pathogens.